Compare USAC & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USAC | INDV |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.4B |
| IPO Year | 2011 | 2014 |
| Metric | USAC | INDV |
|---|---|---|
| Price | $25.71 | $40.30 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $26.67 | N/A |
| AVG Volume (30 Days) | 159.2K | ★ 1.5M |
| Earning Date | 05-05-2026 | 06-08-2026 |
| Dividend Yield | ★ 7.72% | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | N/A | ★ 0.69 |
| Revenue | $698,365,000.00 | ★ $1,239,000,000.00 |
| Revenue This Year | $33.35 | N/A |
| Revenue Next Year | $6.09 | N/A |
| P/E Ratio | ★ $31.25 | $58.73 |
| Revenue Growth | ★ 19.51 | 4.29 |
| 52 Week Low | $21.85 | $16.99 |
| 52 Week High | $30.55 | $42.81 |
| Indicator | USAC | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 43.05 | 53.44 |
| Support Level | $24.56 | $39.20 |
| Resistance Level | $26.01 | $41.42 |
| Average True Range (ATR) | 0.78 | 1.28 |
| MACD | 0.01 | -0.14 |
| Stochastic Oscillator | 15.46 | 54.81 |
USA Compression Partners LP provides compression services in the United States in terms of total compression fleet horsepower to customers relating to infrastructure applications, including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. It engineers, designs, operates, services, and repairs its compression units and maintains related support inventory and equipment. The company provides compression services throughout the U.S., including the Utica, Marcellus, Permian, Denver-Julesburg, Eagle Ford, Mississippi Lime, Granite Wash, Woodford, Barnett, and Haynesville.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).